Explore this article's sources with AI
Follow PeptideMethods on Google
Tirzepatide in SURMOUNT-OSA
SURMOUNT-OSA found large AHI reductions with tirzepatide, alongside weight and blood-pressure changes, but no cardiovascular-event result.
Why we wrote this. The apnea result is clinically relevant, but cardiovascular risk-marker changes should not be mistaken for event prevention.
In this article (5 sections)
The SURMOUNT-OSA programme tested tirzepatide in two 52-week, double-blind, randomized trials involving 469 adults with obesity and moderate-to-severe obstructive sleep apnea. One trial enrolled people who were not using positive airway pressure, or PAP. The other enrolled established PAP users. Compared with placebo, tirzepatide reduced the apnea-hypopnea index by an estimated 20.0 events per hour in the first trial and 23.8 events per hour in the second[1][2]. Those are large changes in disordered breathing. They do not yet show fewer major cardiovascular events or cardiovascular deaths.
The two trials asked different PAP questions
Obstructive sleep apnea repeatedly narrows or closes the upper airway during sleep. The apnea-hypopnea index, or AHI, counts complete and partial breathing interruptions per hour. SURMOUNT-OSA enrolled adults with an AHI of at least 15 events per hour and a body-mass index of at least 30. People with type 1 or type 2 diabetes were excluded. The registry identifies AHI change from baseline to week 52 as the primary outcome and records the combined programme as a completed, randomized phase 3 study[3].
Trial 1 included participants who were unable or unwilling to use PAP. Established PAP users entered trial 2 after at least three consecutive months of therapy and planned to continue it. Those participants paused PAP for seven days before sleep studies and patient-reported assessments so the device would not obscure the measured drug-placebo difference[2]. This design lets the programme address tirzepatide without PAP and alongside established PAP care. It does not establish that medication should replace a working PAP regimen.
Participants were assigned to placebo or the maximum tolerated tirzepatide dose, 10 mg or 15 mg once weekly, after dose escalation. That wording describes the trial protocol, not a dose recommendation. Treatment decisions require a clinician who can account for other medicines, contraindications, adverse effects, and the reason PAP is or is not being used[2].
AHI fell in both trial settings
Mean baseline AHI was 51.5 events per hour in trial 1 and 49.5 in trial 2, indicating severe sleep apnea on average. In trial 1, mean AHI changed by 25.3 events per hour downward with tirzepatide and 5.3 downward with placebo. In trial 2, the respective reductions were 29.3 and 5.5 events per hour. Both placebo-adjusted differences met the prespecified statistical threshold[2].
A responder threshold gives the averages more clinical shape. At week 52, 42.2% of tirzepatide participants in trial 1 reached an AHI below 5, or an AHI from 5 to 14 with little daytime sleepiness, compared with 15.9% on placebo. Trial 2 reported 50.2% and 14.3%, respectively[2]. Many treated participants still had residual sleep apnea, and a lower group average does not guarantee control for an individual.
The programme also measured sleep apnea-specific hypoxic burden, which combines the depth and duration of oxygen drops linked to respiratory events. It fell more with tirzepatide in both trials. Patient-reported sleep impairment and sleep disturbance improved as well[2]. These outcomes support a broader sleep benefit than the event count alone, although they remain 52-week trial measurements rather than evidence of long-term cardiovascular-event prevention.
Weight and blood pressure moved with AHI
Mean body weight fell 17.7% with tirzepatide and 1.6% with placebo in trial 1. Trial 2 reported reductions of 19.6% and 2.3%. Systolic blood pressure at week 48 fell by 9.5 mm Hg versus 1.8 mm Hg in trial 1, and by 7.6 mm Hg versus 3.9 mm Hg in trial 2[2]. High-sensitivity C-reactive protein, an inflammatory marker, also declined more with tirzepatide. None of these secondary measurements is a substitute for a trial designed around cardiovascular events.
The 2026 cardiology review that prompted this article places the readout in a cardiovascular context. It notes the association of obstructive sleep apnea with hypertension, atrial fibrillation, heart failure, and stroke, then summarizes the parallel reductions in AHI, hypoxic burden, body weight, systolic pressure, and high-sensitivity C-reactive protein[1]. For cardiovascular practice, the trial identifies several risk markers that moved in a favorable direction. It offers no randomized estimate for myocardial infarction, stroke, heart-failure hospitalization, arrhythmia, or cardiovascular death.
The mechanism cannot be separated cleanly from weight loss in these data. The FDA's approval notice says the AHI improvement was likely related to body-weight reduction[4]. The trial paper discusses reduced upper-airway obstruction as weight falls, but SURMOUNT-OSA was not designed to isolate direct drug effects from the consequences of losing weight. AHI improvement and cardiometabolic improvement occurred together.
Safety and the approval boundary
Gastrointestinal events were the most frequent adverse effects. Diarrhea occurred in 26.3% and 21.8% of tirzepatide participants across trials 1 and 2; nausea occurred in 25.4% and 21.8%. Serious adverse events occurred in similar proportions across active and placebo groups, and no deaths were reported. Two adjudicated cases of acute pancreatitis occurred in the tirzepatide group in trial 2[2]. A 469-person programme cannot characterize every uncommon or delayed harm.
On 20 December 2024, the FDA approved Zepbound, the US tirzepatide brand, for moderate-to-severe obstructive sleep apnea in adults with obesity, together with a reduced-calorie diet and increased physical activity. The agency based the decision on the two randomized trials and described PAP as standard care for moderate-to-severe disease[4]. Approval applies to that defined US population. Our tirzepatide regulation overview tracks how authorized uses differ by country.
What we don't yet know
SURMOUNT-OSA ran for 52 weeks, excluded diabetes, and enrolled only adults with obesity and moderate-to-severe sleep apnea. The results do not answer whether the same effect applies to lower body-mass ranges, mild sleep apnea, or people with diabetes. They also do not show how much benefit persists after tirzepatide is stopped. Longer follow-up is needed for durability and uncommon safety outcomes.
Cardiovascular risk markers improved, but the primary endpoint was AHI and the registry does not list a cardiovascular-event endpoint[3]. Clinicians can use these results when obesity and sleep apnea overlap, while keeping the evidentiary boundary visible. PAP response, symptoms, weight trajectory, blood pressure, tolerance, and comorbid disease all belong in the same review. Claims about preventing heart attacks or strokes must wait for trials that measure those events.
Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.
Frequently asked
How much did tirzepatide reduce sleep apnea events?
At week 52, the estimated reduction versus placebo was 20.0 AHI events per hour in participants not using PAP and 23.8 events per hour in established PAP users. Individual responses varied, and many participants still had residual sleep apnea.
Did SURMOUNT-OSA prove cardiovascular protection?
No. Blood pressure, body weight, hypoxic burden, and high-sensitivity C-reactive protein improved, but the trials did not measure a cardiovascular-event primary outcome. They cannot establish fewer heart attacks, strokes, hospitalizations, or cardiovascular deaths.
Does tirzepatide replace CPAP or other PAP therapy?
The trials do not establish replacement. One enrolled people unable or unwilling to use PAP, while the other enrolled established PAP users. Treatment choices should account for sleep-study results, PAP response, obesity care, safety, and other medical conditions.
Sources
- [1]Shah et al. Tirzepatide for Obstructive Sleep Apnea: Trial Evidence, Cardiometabolic Effects, and Implications for Cardiovascular Practice. Cardiology in Review. PMID 42897716.Tier 1 · primary↩
- [2]Malhotra et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. New England Journal of Medicine. Full text at PubMed Central, PMCID PMC11598664.Tier 1 · primary↩
- [3]ClinicalTrials.gov NCT05412004: Obstructive Sleep Apnea Master Protocol GPIF, completed phase 3 trial record and results.Tier 1 · primary↩
- [4]FDA Approves First Medication for Obstructive Sleep Apnea, 20 December 2024.Tier 1 · primary↩
No revisions yet. First published .